GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » 50-Day SMA

Nascent Biotech (Nascent Biotech) 50-Day SMA : $0.12 (As of May. 23, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-05-23), Nascent Biotech's 50-Day SMA is $0.12. It's 20-Day SMA is $0.10 and 200-Day SMA is $0.13.


Competitive Comparison of Nascent Biotech's 50-Day SMA

For the Biotechnology subindustry, Nascent Biotech's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's 50-Day SMA falls into.



Nascent Biotech  (OTCPK:NBIO) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech  (OTCPK:NBIO) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Nascent Biotech 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121